Histologically or cytologically confirmed cholangiocarcinoma.
Histologically or cytologically confirmed prostate cancer
Patients must have histologically or cytologically confirmed non-rhabdomyosarcoma of soft tissue or bone at any site
Have histologically or cytologically confirmed SCLC that meets:
Histologically or cytologically confirmed diagnosis of metastatic medullary thyroid cancer
Histologically or cytologically confirmed diagnosis of melanoma.
Histologically or cytologically confirmed SCLC (either limited or extensive disease) or LCNEC, that has relapsed from the most current treatment or was refractory to treatment
Histologically or cytologically confirmed diagnosis of melanoma
Histologically or cytologically confirmed limited or extensive disease stage of SCLC. The disease should be progressing during or relapsing after the previous treatment.
Histologically or cytologically confirmed, treatment-naive esophageal squamous cell carcinoma
Histologically or cytologically confirmed metastatic UM
Histologically or cytologically confirmed AML according to the WHO classification
Histologically or cytologically confirmed diagnosis of prostate cancer
Histologically or cytologically confirmed diagnosis of advanced disease of any of the following tumor types:
Patients must have histologically or cytologically confirmed metastatic or recurrent RCC (any histologic subtype)
Histologically or cytologically confirmed PSCC
Patients must have must have histologically or cytologically confirmed SCLC
Histologically or cytologically confirmed hepatocellular carcinoma or biliary tract cancer.
Histologically or cytologically confirmed diagnosis of early stage prostate cancer
Histologically or cytologically confirmed BRAFV wild-type melanoma
Histologically or cytologically confirmed ovarian epithelial cancer
Histologically or cytologically confirmed prostate carcinoma.
Histologically or cytologically confirmed hematologic malignancy
Subjects with histologically or cytologically confirmed extensive stage disease SCLC
Have histologically or cytologically confirmed diagnosis of pancreatic carcinoma
Diagnosis of histologically or cytologically confirmed metastatic or non-resectable synovial sarcoma
CAPMATINIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanoma
CERITINIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanoma
REGORAFENIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanoma
ENTRECTINIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanoma
Patients must have histologically or cytologically-confirmed diagnosis of progressive or recurrent malignancy as follows:
Histologically or cytologically documented disease
Pathologically (histologically or cytologically) confirmed diagnosis of esophageal squamous cell carcinoma (ESCC)
Histologically or cytologically confirmed
Histologically or cytologically confirmed (patients with mixed histologies are required to have a dominant transitional cell pattern.)
Histologically or cytologically confirmed metastatic or recurrent tumor types
Histologically or cytologically confirmed diagnosis of Ewing sarcoma and have progressed on or after standard therapies.
Histologically or cytologically confirmed solid tumors or hepatocellular carcinoma with known disease progression.
Histologically- or cytologically-confirmed mCRC.
Histologically or cytologically confirmed BRAF- or MEK-mutated melanoma
Patients with histologically or cytologically confirmed metastatic NETs of any origin of low or intermediate grade (Part )
In dose escalation, patients must have histologically or cytologically confirmed metastatic disease from any solid tumor; in dose expansion, patients must have histologically or cytologically confirmed metastatic melanoma, renal cell carcinoma, ovarian cancer, or colorectal cancer
Patients without histologically or cytologically confirmed node metastases or any other metastases
Patients must have histologically or cytologically confirmed peritoneal surface malignancies from primary appendiceal tumors
Histologically or cytologically confirmed transitional cell carcinoma of the genitourinary tract
Histologically or cytologically confirmed carcinoma of the breast
Have histologically or cytologically confirmed melanoma
Patients with a histologically or cytologically confirmed diagnosis of breast cancer; patients must have metastatic HER positive (+) disease
Subject has a definitive histologically or cytologically confirmed diagnosis of HER(-) metastatic breast cancer.
Histologically or cytologically confirmed melanoma.
Histologically or cytologically confirmed metastatic breast cancer
Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group [VALG] staging system)
Histologically or cytologically confirmed diagnosis of pancreatic cancer.
Histologically or cytologically confirmed advanced fibrolamellar carcinoma (FLC).
Inclusion Criteria:\n\n        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please\n        visit www.BMSStudyConnect.com\n\n          -  Patients with metastatic or advanced solid tumors\n\n          -  Women with histologically or cytologically confirmed triple negative breast carcinoma\n\n          -  Participants with histologically or cytologically confirmed pancreatic adenocarcinoma\n\n          -  Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer\n             (NSCLC)\n\n        Exclusion Criteria:\n\n          -  Active brain metastases or leptomeningeal metastases.\n\n          -  Any serious or uncontrolled medical disorder\n\n          -  Prior malignancy active within the previous  years\n\n        Other protocol defined inclusion/exclusion criteria could apply
Histologically or cytologically confirmed carcinoma of the breast
Patients must have histologically or cytologically confirmed evidence of pancreatic carcinoma
Histologically or cytologically confirmed diagnosis of HCC
Histologically or cytologically confirmed metastatic PDAC, no more than  prior chemotherapy regimen or treatment-nave patients
Histologically or cytologically confirmed diagnosis of biliary tract adenocarcinoma/cholangiocarcinoma
Patients must have histologically or cytologically confirmed gastrointestinal (GI) malignancies or ovarian cancer prior to entering this study
Histologically or cytologically confirmed carcinoma of the prostate
Histologically or cytologically confirmed breast cancer with evidence of metastatic disease.
Histologically or cytologically confirmed diagnosis
Patients must have histologically or cytologically confirmed diagnosis of cancer not amenable to curative therapy.
Histologically or cytologically confirmed urothelial carcinoma.
Patients must have histologically or cytologically confirmed cancer
Patient has histologically/cytologically-confirmed HNSCC.
Patients with histologically/cytologically-confirmed HNSCC
Histologically or cytologically confirmed prostate cancer
Histologically or cytologically confirmed disease;
Patient has a histologically and/or cytologically confirmed diagnosis of breast cancer
Participants must have histologically or cytologically confirmed diagnosis of SCLC
Subjects with a histologically or cytologically confirmed acute leukemia who are refractory to or have exhausted all available therapies
Histologically or cytologically documented breast cancer
Histologically or cytologically confirmed melanoma
Histologically or cytologically confirmed locally residual or recurrent cancer of the rectum or anus
Histologically or cytologically confirmed breast carcinoma
Histologically or cytologically confirmed salivary gland carcinoma.
Histologically or cytologically confirmed diagnosis of mCRC
Histologically or cytologically confirmed diagnosis of prostate cancer
Have histologically or cytologically-confirmed malignant disease in an advanced incurable stage
Histologically and/or cytologically confirmed diagnosis of ER+/HER- breast cancer
Histologically or cytologically confirmed, stage I-III breast cancer
Adult patients >  years with histologically or cytologically confirmed Peripheral T-cell lymphoma (PTCL)
Men and women,  years or older, with histologically or cytologically-confirmed either:
Histologically or cytologically confirmed breast cancer
Have histologically or cytologically confirmed small bowel carcinoid tumor
Histologically or cytologically confirmed primary breast cancer.
Age ?  years with histologically- or cytologically-confirmed, extensive-stage, chemotherapy-nave SCLC